ACRO Biomedical, which has profound expertise in the field of regenerative medicine, reached an international collaboration agreement with DKSH (a Swiss company), a world-renowned medical device distributor, in Vietnam on the 20^th. DKSH will be the exclusive distributor in Vietnam for the fields of wound care, dental, orthopedics and general surgery.

According to this strategic agreement, DKSH will be the exclusive distributor in the Vietnamese market for ACRO Biomedical’s Collagen Matrix and Collagen Bone Graft. These two advanced medical materials are commonly used in general surgeries and dental implant surgeries. These products are natural and non-toxic and have excellent biocompatibility, which can provide a more professional option and solution for regenerative medicine in Vietnam. The agreement was initially signed for five years, and the two parties will further discuss future collaboration models based on the performance of the collaboration and market performance. In addition to accelerating the promotion of ACRO Biomedical's products in the Vietnamese market, this collaboration is also expected to bring higher-end innovation to Vietnam's medical industry.

Dr. Dar-Jen Hsieh, CEO of the company, said that in the past two years, ACRO Biomedical has continued to grow and develop in the Vietnamese market. It has collaborated with outstanding local doctors who tried ACRO's Collagen Matrix and Collagen Bone Graft, provided valuable insights, and will continue to promote ACRO Biomedical's products to more Vietnamese doctors. The collaboration between ACRO and DKSH will assist in penetrating more deeply into the Vietnamese medical market and promoting mutual learning between doctors in Taiwan and Vietnam. DKSH believes that ACRO Biomedical's products have huge potential in the Vietnamese market, and this collaboration will give full play to the advantages of both parties and successfully develop the market.

ACRO Biomedical is committed to the research and development of regenerative medicine. With its patented supercritical carbon dioxide decellularization technology, it completely removes cells and impurities from tissues in a natural and non-toxic way without chemicals and cross-linking agents, leaving behind high-end medical biomaterials prepared from natural collagen scaffolds (non-recombinant collagen). This kind of biomaterials have good biocompatibility and are currently the best repair materials for the human body. The Collagen Matrix can be used as surgical wound dressing, dental implant for soft-tissue augmentation. The Collagen Bone Graft is used to repair bone defects or filling of hard tissue defects in dental implant surgery.

As we all know, DKSH Holding is a leading market expansion service provider with a focus on Asia, helping businesses grow in existing markets and expand into new ones. In addition to signing a contract with DKSH, a local medical distributor that has been working for over a century in Vietnam, ACRO has also signed a MOU with the Ministry of Health of Vietnam to collaborate on human clinical trials and certification of its decellularized cornea product in Vietnam. It is believed that the international strategic cooperation with DKSH will not only benefit ACRO Biomedical’s overall revenue, but also increase ACRO’s brand value internationally. ACRO Biomedical is actively planning for its listing in the third quarter.